of0
Export
 
CDE Detailed Report
This report contains detailed information about the selected CDEs.
Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report.
Disease: Facioscapulohumeral Muscular Dystrophy
Sub-Domain: Muscle Strength Testing
CRF: Grip Strength
Item count: 8 (8 distinct CDEs)
CDE ID
CDE Name
Variable Name
Definition / Description
Question Text
Permissible Value
Description
Data Type
Instructions
References
Population
Classification (e.g., Core)
Version #
Version Date
Aliases for Variable Name
CRF Module / Guideline
© or TM
Sub-Domain
Domain
Previous Title
Size
Input Restrictions
Min Value
Max Value
Measurement Type
LOINC ID
SNOMED
caDSR ID
CDISC ID
C10851
Grip strength test indicator
GripStrengthTestInd
Indicator whether the grip strength testing was done
Was hand grip strength testing performed?
Yes;No;
Yes;No;
Alphanumeric
Choose one.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.
Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467. Epub 2010/09/11. doi: 10.1136/bmj.c4467. PubMed PMID: 20829298; PubMed Central PMCID: PMC2938886.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/22/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Grip strength testing performed indicator
 
Single Pre-Defined Value Selected
       
C10852
Grip strength test performed date and time
GripStrengthTestPerfDateTime
Date (and time, if applicable and known) that grip strength testing was done
Date Performed
  
Date or Date & Time
Record the date/time according to the ISO 8601, the International Standard for the representation of dates and times (ISO 8601 - https://www.iso.org/iso-8601-date-and-time-format.html). The date/time should be recorded to the level of granularity known (e.g., year, year and month, complete date plus hours and minutes, etc.)

This CDE is highly recommended for FSHD studies involving muscle strength testing.
ISO 8601 - https://www.iso.org/iso-8601-date-and-time-format.html

Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.

Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/22/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Grip strength performed date and time
 
Free-Form Entry
       
C00023
Hand preference type
HandPrefTyp
Hand which the participant/subject uses predominantly, not necessarily the hand he/she writes with exclusively.
Handedness
Left hand;Right hand;Both hands;Unknown;
Left hand;Right hand;Both hands;Unknown;
Alphanumeric
Choose one. The predominant hand does not have to be the hand that he/she writes with. Unknown should be used in the scenario for infants or other (rare) instances when handedness can not be known or is not yet developed.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.
Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/25/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Hand preference type
 
Single Pre-Defined Value Selected
     
2180147
 
C02411
Laterality type
LatTyp
Laterality type relative to the anatomic site of the body examined or affected
Grip Strength Hand
Right;Left;
Right;Left;
Alphanumeric
Record the grip strength results for each hand side.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.

Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
8/28/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Laterality type
 
Single Pre-Defined Value Selected
       
C10854
Grip device width setting value
GripDeviceWidthSettingVal
Value of the width setting on the grip device used to test the participant/subject's grip strength
Grip Device Width Setting
  
Numeric Values
Record setting on grip strength instrument for each side.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.

Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467. E

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/22/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Grip strength device width setting value
 
Free-Form Entry
       
C10171
Trial number
TrialNum
The number representing the sequence for any repeated measure test or assessment when it is performed multiple times.
Trial
Trial 1;Trial 2;
Trial 1;Trial 2;
Alphanumeric
It is recommended that two trials be used to measure grip strength.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Bohannon RW. Hand-Held Dynamometry; Stability of Muscle Strength Over Multiple Measurements. Clinical Biomechanics. 1986: 2:74-77.

Wang CY, Olson SL, Protas EJ. Test-Retest Strength Reliability: Hand-Held Dynamometry in Community-Dwelling Elderly Faller. Arch Phys Med Rehabil. 2002; 83: 811-5.

Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.

Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/25/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Trial number
 
Single Pre-Defined Value Selected
       
C10855
Grip strength maximum measurement
GripStrengthMaxMeasr
Measurement of the maximum grip strength attained in the trial being recorded
Max Grip
  
Numeric Values
Answer for each hand side in pounds, kilograms or newtons.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.

Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/22/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Grip strength maximum measurement
 
Free-Form Entry
       
C10856
Grip strength unit of measure
GripStrengthUOM
Unit of measure (pounds, kilograms, or newtons) for the maximum grip strength attained or for the target in the trial being recorded
Indicate units: pounds, kilograms, or newtons
lb;kg;N;
Pounds;Kilograms;Newtons;
Alphanumeric
Choose one for each grip strength measurement.

This CDE is highly recommended for FSHD studies involving muscle strength testing.
Personius, K. E., S. Pandya, et al. (1994). "Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group." Phys Ther 74(3): 253-263.

Kissel, J. T., M. P. McDermott, et al. (2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy." Neurology 57(8): 1434-1440.
Wagner, K. R., J. L. Fleckenstein, et al. (2008). "A phase I/Iitrial of MYO-029 in adult subjects with muscular dystrophy." Ann Neurol 63(5): 561-571.

van der Kooi, E. L., O. J. Vogels, et al. (2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy." Neurology 63(4): 702-708.

Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.

Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, et al. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. The journals of gerontology Series A, Biological sciences and medical sciences. 2006;61(1):72-77.
Adult;Pediatric
Supplemental
3.0
7/22/2013
Aliases for variable name not defined
Grip Strength
Muscle Strength Testing
Outcomes and End Points
Grip strength unit of measure
 
Single Pre-Defined Value Selected
       
07-22-2019
Page 1 of 1